Back to School: How biopharma can reboot drug development. Access exclusive analysis here

M-Enoxaparin not approvable

Momenta (MNTA) was off $7.71 (58%) to $5.67 on 17.6 million shares after

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE